News

BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate

The safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) is being evaluated in the study. Merck will sponsor the trail,

UCART19 uses Cellectis’ allogeneic approach to develop CAR-T therapies that engineer T-cells from non-patient donors for use in several patients. The immunotherapy candidate is about to enter Phase

The approval was based on data from pivotal Phase 3 ASPIRE trial which showed that patients treated with Kyprolis in combination lived nearly nine months longer without disease

The spray, which is expected to be launched in early 2016, is an investigational drug designed to provide a dose of naloxone in a nasal spray formulation. It

The Pilot Longitudinal Study in Alzheimer’s Disease of Central Markers of Microglial Activation (PADMMA) combines brain imaging with key biomarkers to identify the role of inflammation in neurodegenerative

As part of this plan, the Company has signed two collaborations, one with the Croix-Rousse Hospital, Hepato-Oncology Team and the Centre de Recherche en Cancérologie, Inserm U1052, in

The IND will enable Janssen, Aduro’s license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741

AZD2811, a novel, selective inhibitor of Aurora B kinase that has been shown to be active in both solid and hematological tumors in preclinical models, is the second